Stock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback

Stock Track

01-08

Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.

In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:

Total revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.
Adjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.
Non-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.

Halozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1198807458"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198807458\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1198807458?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198807458","market":"us","top_or_hot":-1,"title":"Stock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback","media":"Stock Track","content":"<p>Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.</p>\n\n<p>In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:</p>\n\n<ul>\n<li>Total revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.</li>\n<li>Adjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.</li>\n<li>Non-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.</li>\n</ul>\n\n<p>Halozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-01-08 21:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.</p>\n\n<p>In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:</p>\n\n<ul>\n<li>Total revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.</li>\n<li>Adjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.</li>\n<li>Non-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.</li>\n</ul>\n\n<p>Halozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奧洛茲美醫療","start_time":0,"source_url":"","article_id":"1198807458","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198807458","pubTimestamp":1736341701,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Halozyme Therapeutics  stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:. Total revenue is ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"股票赛道Halozyme因提高2025年指引和股票回购而盘前飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.\nIn a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:\n\nTotal revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.\nAdjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.\nNon-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.\n\nHalozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"buyback,movement","news_rank":0,"symbols":[],"gpt_button":1}}}